1 citations
,
January 2018 in “Türkiye klinikleri tıp bilimleri dergisi” The patient characteristics at a private dermatology clinic were similar to those at public or university clinics.
January 2026 in “Journal of Contemporary Medicine” Vitamin D may help prevent or reduce hair loss after COVID-19.
December 2025 in “Çukurova medical journal (Online)/Çukurova medical journal” Certain genetic markers and low vitamin D3 levels are linked to male pattern baldness.
May 2025 in “Afyon Kocatepe University Journal of Sciences and Engineering” The treatment process effectively removes many pollutants from cosmetics wastewater, but more research is needed to improve it.
April 2025 in “Düzce Tıp Fakültesi Dergisi” Vitamin D deficiency is common in children with non-scarring alopecia, and managing it may help treatment.
September 2024 in “Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi” XGBoost can effectively diagnose PCOS with 87% accuracy.
May 2023 in “Journal of contemporary medicine” Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
January 2023 in “Türkiye klinikleri adli tıp ve adli bilimler dergisi” DNA markers can help predict male pattern baldness, useful in criminal and missing person cases.
April 2022 in “SDÜ Tıp Fakültesi Dergisi” Sodium benzoate at higher doses can harm kidney and liver functions and cause oxidative stress and DNA damage.
Using hair gel is an effective and patient-friendly way to keep hair out of the way during ear surgery.
January 2019 in “Türkiye klinikleri dermatoloji dergisi” Low levels of iron, ferritin, zinc, and folic acid may contribute to hair loss in women.
May 2018 in “DergiPark (Istanbul University)” Hormone levels studied are not linked to PCOS.
January 2017 in “Turkiye Klinikleri Journal of Dermatology” Low vitamin D levels, not ferritin levels, were found in patients with hair loss condition telogen effluvium.
January 2017 in “Turkiye Klinikleri Journal of Dermatology” A 9-month-old baby had a rare, persistent ring-shaped hair loss condition.
1 citations
,
March 1997 in “Fertility and Sterility” Finasteride is effective and safe.
January 2017 in “Clinical pharmacist” Long use of finasteride and dutasteride can cause long-term erection problems.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
6 citations
,
September 2010 in “Current Urology Reports” New treatments for long-lasting erections improve outcomes but must be timely to avoid lasting damage.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
January 2011 in “Reactions Weekly” St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.
January 2022 in “Galenika Medical Journal” Medications improve quality of life for men with lower urinary tract symptoms.
February 2025 in “International Journal of Impotence Research” January 2005 in “Fuzhou daxue xuebao. Ziran kexue ban” The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
January 2021 in “Thieme Medical and Scientific Publishers Private Limited eBooks” March 2025 in “Carbohydrate Polymer Technologies and Applications” The new method improves finasteride's effectiveness for hair loss treatment.
34 citations
,
September 2013 in “Urology” Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.